

Ethics Approval Received, New Clinical Trial Site Contracted and Recruiting

- **Illawarra Health & Medical Research Institute has joined the ColoSTAT® clinical trial;**
- **Professor Philip Clingan OAM appointed as Principal Investigator; and**
- **First patient recruited.**

23 September 2020, Melbourne: Illawarra Health & Medical Research Institute, based at the University of Wollongong, has become the sixth site to join the Rhythm Biosciences Limited (ASX:RHY) prospective clinical trial of ColoSTAT®, its global, low-cost, blood test for the early detection of colorectal cancer.

The Illawarra Health & Medical Research Institute (IHMRI) is an independent medical research institute, partnering with the University of Wollongong and the Illawarra-Shoalhaven Local Health District. The institute is a member of the Association of Australian Medical Research Institutes (AAMRI), a peak body for medical research across Australia.

IHMRI's has a well-equipped Clinical Research and Trials unit, and with the Illawarra-Shoalhaven regions stable and accessible population base, makes it an ideal additional location for the ongoing recruitment into Rhythm's clinical trial.

Professor Philip Clingan OAM has been appointed the Principal Investigator for the site. As a Medical Oncologist and Director of the Department of Medical Oncology at the Illawarra-Shoalhaven Local Health District, he brings a wealth of experience and research on cancer, clinical trials and the development of new treatments.

"The burden of colorectal cancer and the benefits of early detection have been well recognised. The risk of colorectal cancer increases dramatically over 50 years of age, yet the majority of people in this age group remain unscreened. A blood-based diagnostic tool such as ColoSTAT® would likely enable more people to participate in screening and thereby could have a significant beneficial impact on colorectal cancer survival rates." said Professor Clingan.

"The appointment of the Illawarra Health & Medical Research Institute is another positive step forward for our clinical trial recruitment. With such a large patient catchment area, we anticipate this site will provide a welcome boost to the recruitment process" commented Rhythm CEO Glenn Gilbert.

With the authority of the Board.

Rhythm BiosciencesACN: 619 459 335
ASX: RHY**Issued Capital**201,495,811 Shares
6,650,000 Options**Australian Registered Office**Level 2, 480 Collins Street
Melbourne VIC 3000
www.rhythmbio.com**Directors**Otto Buttula – Chairman of the Board
Trevor John Lockett – Executive Director
Louis James Panaccio – Non-Executive Director
David John White – Non-Executive Director
Eduardo Vom – Non-Executive Director

For further information, please contact:

Glenn Gilbert
Chief Executive Officer
+61 3 8256 2880

About Rhythm Biosciences

ASX-listed Rhythm Biosciences is endeavoring to develop and commercialise a screening and diagnostic test for the early detection of colorectal cancer, the third biggest cause of cancer-related deaths globally.

Rhythm's lead product, ColoSTAT[®], is intended to be a simple, affordable, minimally invasive and effective blood test for the early detection of bowel cancer for the global mass market. It is expected to be comparable to, if not better than, the current standard of care, the faecal immunochemical test (FIT), at a lower overall cost to public health administrations. ColoSTAT[®] also provides an alternative for those who choose not to, or are unable to, be assessed using standard screening programs.

ColoSTAT[®] is designed to be equipment agnostic and easily used by laboratories without the need for additional operator training or additional infrastructure.

ColoSTAT[®] has the potential to play an important role in reducing the morbidity and mortality rates and healthcare costs associated with colorectal cancer. Globally, over 850,000 people die from colorectal cancer each year.